从药学视角探讨间充质干细胞产品研发的策略与进展

基础医学与临床 ›› 2021, Vol. 41 ›› Issue (9): 1338-1341.

从药学视角探讨间充质干细胞产品研发的策略与进展

李晓静¹, 王丽², 赵春华³, 柳仁民¹, 马胜军⁴, 李光耀⁴, 任少达^4*

聊城大学 1. 药学院; 2. 医学院,山东聊城 252000;
3.北京协和医学院基础学院, 北京 100005;
4.聊城市人民医院干细胞临床研究实验室, 山东聊城 252000

收稿日期:2020-04-27 修回日期:2020-10-10 出版日期:2021-09-05 发布日期:2021-09-02
通讯作者: *zslrsd@163.com
基金资助:
国家自然科学基金(81600087);山东省自然科学基金(ZR2016HB45)

Discussion on development strategy and progress of mesenchymal stem cell products from pharmacy perspective

LI Xiao-jing¹,WANG Li²,ZHAO Chun-hua³,LIU Ren-min¹,MA Sheng-jun⁴,LI Guang-yao⁴,REN Shao-da^4*

1. School of Pharmacy; 2. School of Medicine, Liaocheng University, Liaocheng 252000;
3. School of Basic Medicine, PUMC, Beijing 100005;
4. Stem Cell Clinical Research Laboratory, Liaocheng People's Hospital, Liaocheng 252000, China

Received:2020-04-27 Revised:2020-10-10 Online:2021-09-05 Published:2021-09-02
Contact: *zslrsd@163.com

摘要/Abstract

摘要： 干细胞治疗研究应用开始向“药物”管理模式转变,借鉴传统药学思路将有益于干细胞产品的研究和开发。本文以间充质干细胞(MSCs)产品为例,从药物化学、药剂学、药物分析学与药代动力学等药学学科的角度探讨制约干细胞产品的研发的问题,为未来干细胞药物的发展开拓思路。

关键词: 间充质干细胞, 细胞药物, 药学

Abstract: The stem cell products has been transforming from research into drug therapy, which will benefit from traditional pharmaceutical ideas. Taking mesenchymal stem cells(MSCs) products as an example, this paper discusses the problems restricting the development of stem cell products from the perspectives of various pharmaceutical disciplines, such as medicinal chemistry, pharmaceutics, pharmaceutical analysis and pharmacokinetics, so as to provide a new strategy and pathway for the development of stem cell products in the future.

Key words: mesenchymal stem cell, cell drug, pharmaceutical science

中图分类号:

R329

李晓静, 王丽, 赵春华, 柳仁民, 马胜军, 李光耀, 任少达. 从药学视角探讨间充质干细胞产品研发的策略与进展[J]. 基础医学与临床, 2021, 41(9): 1338-1341.

LI Xiao-jing,WANG Li,ZHAO Chun-hua,LIU Ren-min,MA Sheng-jun,LI Guang-yao,REN Shao-da. Discussion on development strategy and progress of mesenchymal stem cell products from pharmacy perspective[J]. Basic & Clinical Medicine, 2021, 41(9): 1338-1341.

参考文献

[1]Brown C, McKee C, Bakshi S, et al. Mesenchymal stem cells: cell therapy and regeneration potential[J]. J Tissue Eng Regen Med, 2019, 13: 1738-1755.
[2]Pittenger MF, Discher DE, Peault BM, et al. Mesenchymal stem cell perspective: cell biology to clinical progress[J]. NPJ Regen Med, 2019, 4: 22. doi: 10.1038/s41536-019-0083-6.
[3]Guadix JA, Lopez-Beas J, Clares B, et al. Principal criteria for evaluating the quality, safety and efficacy of hMSC-based products in clinical practice: current approaches and challenges[J]. Pharmaceutics, 2019, 11: 552. doi: 10.3390/pharmaceutics11110552.
[4]Wang M, Yuan Q, Xie L. Mesenchymal stem cell-based immunomodulation: properties and clinical application[J]. Stem Cells Int, 2018, 2018: 3057624. doi:10.1155/2018/3057624.
[5]Yousefi F, Lavi Arab F, Nikkhah K, et al. Novel approaches using mesenchymal stem cells for curing peripheral nerve injuries[J]. Life Sci, 2019, 221: 99-108.
[6]Poltavtseva RA, Poltavtsev AV, Lutsenko GV, et al. Myths, reality and future of mesenchymal stem cell therapy[J]. Cell Tissue Res, 2019, 375: 563-574.
[7]Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2(-) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia[J]. Aging Dis, 2020, 11: 216-228.
[8]Mo M, Wang S, Zhou Y, et al. Mesenchymal stem cell subpopulations: phenotype, property and therapeutic potential[J]. Cell Mol Life Sci, 2016, 73: 3311-3321.
[9]Najar M, Bouhtit F, Melki R, et al. Mesenchymal stromal cell-based therapy: new perspectives and challenges[J]. J Clin Med, 2019, 8: 626. doi:10.3390/jcm8050626.
[10]Ocansey DKW, Pei B, Yan Y, et al. Improved therapeutics of modified mesenchymal stem cells: an update[J]. J Transl Med, 2020, 18: 42. doi: 10.1186/s12967-020-02234-x.
[11]Kim DS, Jang IK, Lee MW, et al. Enhanced immunosuppressive properties of human mesenchymal stem cells primed by interferon-gamma[J]. EBioMedicine, 2018, 28: 261-273.
[12]Huang XP, Ludke A, Dhingra S, et al. Class II transactivator knockdown limits major histocompatibility complex II expression, diminishes immune rejection, and improves survival of allogeneic bone marrow stem cells in the infarcted heart[J]. FASEB J, 2016, 30: 3069-3082.
[13]Yin N, Wang Y, Ding L, et al. Platelet-rich plasma enhances the repair capacity of muscle-derived mesenchymal stem cells to large humeral bone defect in rabbits[J]. Sci Rep, 2020, 10: 6771. doi: 10.1038/s41598-020-63496-5.
[14]Vasile C, Pamfil D, Stoleru E, et al. New developments in medical applications of hybrid hydrogels containing natural polymers[J]. Molecules, 2020, 25:1539. doi: 103390/molecules25071539.
[15]Deak E, Ruster B, Keller L, et al. Suspension medium influences interaction of mesenchymal stromal cells with endothelium and pulmonary toxicity after transplantation in mice[J]. Cytotherapy, 2010, 12: 260-264.
[16]Gurung S, Deane JA, Darzi S, et al. In vivo Survival of human endometrial mesenchymal stem cells transplanted under the kidney capsule of immunocompromised mice[J]. Stem Cells Dev, 2018, 27: 35-43.
[17]Andrzejewska A, Jablonska A, Seta M, et al. Labeling of human mesenchymal stem cells with different classes of vital stains: robustness and toxicity[J]. Stem Cell Res Ther, 2019, 10: 187. doi: 10.1186/s13287-019-1296-8.
[18]Dhada KS, Hernandez DS, Suggs LJ. In vivo photoa-coustic tracking of mesenchymal stem cell viability[J]. ACS Nano, 2019, 13: 7791-7799.
[19]Mohseni M, Shojaei S, Mehravi B, et al. Natural polymeric nanoparticles as a non-invasive probe for mesenchymal stem cell labelling[J]. Artif Cells Nanomed Biotechnol, 2020, 48: 770-776.
[20]Brooks A, Futrega K, Liang X, et al. Concise review: quantitative detection and modeling the in vivo kinetics of therapeutic mesenchymal stem/stromal cells[J]. Stem Cells Transl Med, 2018, 7: 78-86.
[21]Fabian C, Naaldijk Y, Leovsky C, et al. Distribution pattern following systemic mesenchymal stem cell injection depends on the age of the recipient and neuronal health[J]. Stem Cell Res Ther, 2017, 8: 85. doi: 10.1186/s13287-017-0533-2.